News
India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...
The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...
Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...
Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.
Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...
The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...
Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
As weight loss medications like Ozempic continue to gain popular, experts and patients are noticing varying effects of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results